Ardelyx, Inc., a specialized biopharmaceutical company, develops and sells medicines for the treatment of cardio renal diseases in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial for the treatment of hyperphosphatemia in end-stage renal disease patients on dialysis. It also develops RDX013, a small molecule potassium secretagogue program for the treatment of patients with hyperkalemia. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was founded in 2007 and is headquartered in Fremont, California.

• Download SqueezeTrigger (TM) Report
• Download FrictionFactor Report
• Download Daily Short Volume Report
• Download Real-Time Short Volume Tool
• Download Failures to Deliver

• [11/12/2019 12:00 PST] ARDX Expected to Trade Up After Bullish Patterns Develop
• [11/08/2019 11:45 PST] Ardelyx, Inc. (NASDAQ:ARDX), Up By 100.00% ($5.01) From $5.010 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [11/04/2019 09:51 PST] Ardelyx, Inc. (NASDAQ:ARDX), Up By 100.00% ($4.41) From $4.410 After BUYINS.NET Report Predicted Stock Would Go Up Due To Bullish Conditions
• [10/29/2019 07:47 PDT] ARDX Expected to Trade Up After Bullish Patterns Develop
• [10/16/2019 07:42 PDT] ARDX Expected to Trade Up After Bullish Patterns Develop
• [09/26/2019 07:39 PDT] ARDX Expected to Trade Up After Bullish Patterns Develop
• [09/13/2019 21:17 PDT] Market Maker Surveillance Report. ARDX, Losing Stocks With Lowest Price Friction For Friday, September 13th 2019